派格生物醫藥（杭州）股份有限公司 董事會提名委員會工作細則 第一章 總則 第一條 為規範派格生物醫藥（杭州）股份有限公司（以下簡稱「公司」）董事 及高級管理人員的產生，優化董事會組成，完善公司治理結構，根據《中華人民 共和國公司法》（以下簡稱「《公司法》」）、《香港聯合交易所有限公司證券上市規 則》（以下簡稱「《上市規則》」）、《上市規則》附錄C1所載的《企業管治守則》等相關 法律、法規、規範性文件及H股發行後適用的《派格生物醫藥（杭州）股份有限公 司章程》（以下簡稱「《公司章程》」），公司設立董事會提名委員會，並結合公司實 際，制定本《派格生物醫藥（杭州）股份有限公司董事會提名委員會工作細則》（以 下簡稱「本細則」）。 第二條 提名委員會是董事會下設的專門工作機構，主要職責是對董事（包 括獨立非執行董事）及高級管理人員的選擇、選擇標準和程序進行研究並向董事 會提出意見和建議。 本細則所稱高級管理人員，是指總經理、副總經理（根據公司需要聘請）、財 務總監、董事會秘書以及由董事會聘任為高級管理人員的其他人員。本細則所稱 「總經理」即《公司法》所稱「經理」。 第四條 委員由董事長或三分之一以上董事聯合提名，並由董 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2025年12月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | | 是 | | | 證券代號 (如上市) | 02565 | 說明 | H股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 佔有關事件前的現有已發 | | 庫存股份變動 | 每股發行/出售價 (註4) | | 已發行股份總 ...

Group 1 - The core viewpoint of the article is that Pagoda Biopharmaceuticals-B (02565) has successfully completed a placement agreement on December 22, 2025 [1] - The placement involved the issuance of 5.136 million shares at a price of HKD 58.41 per share [1] - This placement represents approximately 1.81% of the enlarged H-shares and about 1.31% of the total shares post-placement [1]

Core Viewpoint - The company, Pagoda Biopharmaceuticals-B (02565), has successfully completed a placement agreement, with all conditions met as of December 22, 2025 [1] Group 1: Placement Details - The joint placement agents sold a total of 5.136 million shares at a price of HKD 58.41 per share [1] - This placement represents approximately 1.81% of the enlarged H-share capital and about 1.31% of the total share capital post-placement [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。 （股份代號：2565） 本公告或其任何副本，均不得直接或間接在美國境內發佈或分發，亦不得在任何其他司法管轄 區內發佈或分發，而此類發佈或分發於該等司法管轄區可能屬違法。 本公告並不構成在美國購買或認購證券的任何要約或要約招攬，亦不構成其一部分。本公告所 述證券並無亦不會根據1933年美國證券法（經修訂）（「美國證券法」）或美國任何其他適用證券 法律登記，且除非已根據美國證券法登記，或依照美國證券法或美國任何其他適用證券法律獲 豁免登記，或在無須根據美國證券法或美國任何其他適用證券法律登記的交易中，否則不得在 美國發售、出售或以其他方式轉讓。本公司無意在美國進行任何證券公開發售。 PegBio Co., Ltd. 派格生物醫藥（杭州）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 完成根據一般授權配售新H股 茲提述派格生物醫藥（杭州 ...

Core Viewpoint - The company has received notification from cornerstone investor Yizhe Kangrui Pharmaceutical (Hong Kong) Co., Ltd. agreeing to extend the lock-up period until April 30, 2026, indicating confidence in the company's future prospects based on its technological advancements and significant clinical milestones achieved [1] Group 1 - The cornerstone investor holds a total of 9.5845 million H-shares, representing approximately 3.43% of the company's total issued H-shares [1] - The extension of the lock-up period reflects the cornerstone investor's confidence in the company's research and development capabilities [1] - The cornerstone investor will continue to review the company's performance and may consider further extending the lock-up period based on real-time developments and achieved milestones [1]

Group 1 - The company has entered into a placement agreement with joint placement agents to issue 5.136 million shares at a price of HKD 58.41 per share, targeting at least six subscribers [2] - The placement shares represent approximately 1.84% of the issued H shares and about 1.33% of the total issued shares as of the announcement date, and will account for approximately 1.81% of H shares and 1.31% of total shares post-issuance [2] Group 2 - The placement price of HKD 58.41 per share reflects a 10% discount compared to the closing price of HKD 64.90 per share on December 12, 2025 [3] - The estimated net proceeds from the placement are approximately HKD 296 million, with around 40% allocated for building a next-generation intelligent R&D and data platform, 28% for loan repayment and strengthening capital structure, 12% for ongoing and planned R&D of PB-2301 and PB-2309, 10% for establishing a subsidiary in Hong Kong and accelerating overseas business expansion, and 10% for general corporate purposes and working capital [3]

Core Viewpoint - The announcements from Paig Bio-B (02625) reflect a dual approach of "confidence" and "aggressiveness," with cornerstone shareholders voluntarily locking their shares to express long-term confidence in the company's development while also initiating a placement to raise funds for future expansion [1][2]. Group 1: Cornerstone Shareholder Lock-up - Cornerstone investors have voluntarily extended their share lock-up period to April 30, 2024, demonstrating their strong confidence in the company's R&D capabilities and progress towards significant clinical milestones [2]. - This extension indicates that cornerstone investors are not merely financial speculators but rather long-term value investors, willing to forgo liquidity to support the company's growth [2]. - The timing of the lock-up extension suggests it may coincide with key R&D milestones or potential international collaborations, reflecting the investors' expectations for positive developments [2]. Group 2: Fundraising Strategy - Paig Bio plans to raise nearly HKD 300 million through a share placement at HKD 58.41 per share, with the offering managed by several prominent institutions [3]. - The funds are earmarked for strategic development rather than immediate financial relief, with a focus on four key areas: digital transformation in R&D, financial health, pipeline sustainability, and operational reserves [3][4]. - The first area, digital transformation, will consume HKD 118 million (40% of the total), aimed at enhancing drug discovery through AI and data integration [3][4]. Group 3: Financial Health and Pipeline Development - The second area focuses on financial health, allocating 28% of the funds to repay bank loans, thereby reducing interest expenses and improving cash flow [4]. - The third area emphasizes pipeline sustainability and internationalization, with 12% and 10% of the funds respectively directed towards advancing products PB2301/PB2309 and establishing a subsidiary in Hong Kong for global expansion [4][5]. - The final area, operational reserves, will account for 10% of the funds, preparing the company for the upcoming commercialization phase [5]. Group 4: Market Perception and Future Outlook - The combination of the fundraising initiative and the cornerstone investors' support creates a positive feedback loop, reducing uncertainties associated with the placement and shifting market focus from short-term dilution to long-term value creation [6]. - The management's proactive approach, coupled with the backing from cornerstone investors, positions Paig Bio favorably for future growth and innovation, making it a company to watch in the industry [6].

格隆汇12月15日丨派格生物医药-B(02565.HK)发布公告，近日，公司接获基石投资者的通知，据此，基 石投资者同意自原禁售期(经第一次禁售延长予以延长)届满日期起至2026年4月30日不会以任何方式减 持任何相关H股("第二次禁售延长")。公司认为，第二次禁售延长表明基石投资者基于公司对推进技术 方面的研发能力及在重大临床里程碑方面取得的重大进展，对公司的未来前景充满信心。基石投资者亦 将持续审阅公司业绩，且或会基于实时发展及所实现的里程碑，考虑进一步延长禁售期。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公告由派格生物醫藥（杭州）股份有限公司（「本公司」）自願刊發。 茲提述本公司日期為2025年5月19日的招股章程、本公司日期為2025年5月26日 的最終發售價及配發結果公告及本公司日期為2025年11月26日的公告，內容有關 （其中包括）(i)本公司與益澤康瑞醫藥（香港）有限公司（「基石投資者」）訂立的基 石投資協議；(ii)基石投資者就合共9,584,500股本公司H股作出自上市日期（包括 該日）起計六個月期間（「原禁售期」）的禁售承諾；及(iii)原禁售期延長至2025年 12月31日（「第一次禁售延長」）。 原禁售期的最後一天（經第一次禁售延長予以延長）為2025年12月31日。截至本 公告日期，基石投資者合共持有9,584,500股H股，佔本公司已發行H股總數約 3.43%（「相關H股」）。 近日，本公司接獲基石投資者的通知，據此，基石投資者同意自原禁售期（經第 一次禁售延長予以延長）屆滿日期 ...